View by Category
About This Presentation



Read here the market research report on the “Hypertriglyceridemia Therapeutics Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:4
Date added: 4 November 2020
Slides: 18
Provided by: kunalbhuta
Category: Other


Write a Comment
User Comments (0)
Transcript and Presenter's Notes


  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

  • Hypertriglyceridemia Therapeutics Market, by Type
    (Primary and Secondary), by Drug Class (Statins,
    Fibrates, Niacin, Omega-3 Fatty Acids, and
    HMG-CoA Reductase inhibitors), by Distribution
    Channel (Online Pharmacy, Retail Pharmacy,
    Hospital Pharmacy, and Others), and by Region
    (North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa) - Size, Share,
    Outlook, and Opportunity Analysis, 2020 - 2027

  • Hypertriglyceridemia is a common disorder or
    condition in which the triglyceride levels in the
    blood are elevated. The increasing levels of
    triglyceride are mainly related to
    atherosclerosis and cardiovascular diseases
    (CVDs). This condition also causes
    pancreatitis, atherosclerosis, and other CVDs.
    New advancements in terms of diagnosis and
    treatment of hypertriglyceridemia for rapidly
    recovering the triglyceride levels in the human
    body are expected to boost the global
    hypertriglyceridemia therapeutics market growth.
  • The key players are investing in research
    development and commercialization of novel drugs
    for the treatment of hypertriglyceridemia, which
    is expected to boost the market growth during the
    forecast period. Moreover, the growing prevalence
    of cardiovascular diseases and increasing
    sedentary habits are other factors propelling the
    market growth. For instance, according to the
    World Health Organization (WHO), around 17.9
    million deaths reported in 2016 were due to
    cardiovascular diseases which are the leading
    cause of death across the globe.

Global Hypertriglyceridemia Therapeutics Market -
Impact of Coronavirus (Covid-19) Pandemic
  • The hypertriglyceridemia therapeutics market
    growth has been impacted significantly due to the
    outbreak of COVID-19 across the world. As per the
    EMCrit Project, COVID-19 affected patients are
    more prone to developing hypertriglyceridemia,
    mainly due to systemic inflammation. Thus,
    ideally keeping the propofol dosages can help to
    maintain sedation and prevent conditions such as
    hypertriglyceridemia. It is becoming difficult
    for researchers and key industry players to
    perform clinical trials during this pandemic
    crisis. However, many market players such as Eli
    Lilly and Company, and Pfizer Inc. are investing
    in research and development of novel
    hypertriglyceridemia drugs.

  • The all-inclusive version of the report will
    include the impact of COVID-19 and the probable
    changes in the future outlook of the industry, by
    taking into account the technological, social,
    political, and economical parameters.
  • The hypertriglyceridemia therapeutics market is
    estimated to be valued at US 9,716.6 million in
    2020 and is expected to register a CAGR of
    4.09 during the forecast period (2020-2027).

Figure 1. Global Hypertriglyceridemia
Therapeutics Market Share () Analysis, By Type,
  • The increasing research development of drugs
    are expected to propel the global
    hypertriglyc eridemia therapeutics market growth
    during the forecast period
  • Key players are investing to in development of
    novel drugs and launching these products in the
    market which in turn, is estimated to
    significantly boost the market growth and create
    lucrative growth opportunities in the global
    hypertriglyceridemia therapeutics market during
    the forecast period.

  • For instance, in July 2019, Sun Pharma launched
    Ezallor Sprinkle (Rosuvastatin) in the U.S. for
    the people having difficulty swallowing. Ezallor
    Sprinkle capsules are indicated as an adjunct to
    the diet for the hypertriglyceridemia adult
    patients treatment. It is also indicated as an
    adjunct to diet for the treatment of adult
    patients with type III hyperlipoproteinemi and to
    other lipid-lowering treatments.
  • Furthermore, the increasing number of drug
    approvals are expected to help companies
    strengthen their market position. For instance,
    in December 2019, Amarin received FDA approval
    for VASCEPA (icosapent ethyl) indicated for
    reducing cardiovascular risk. The novel
    indication for VASCEPA is that it is an adjunct
    to diet to reduce triglyceride levels in older
    patients with severe hypertriglyceridemia.

(No Transcript)
Hypertriglyceridemia Therapeutics Market
Regional Analysis
  • North America accounted for majority of the share
    in the global hypertriglyceridemia therapeutics
    market in 2019 and is expected to retain its
    dominance during the forecast period. This is
    majorly attributed to the growing healthcare
    expenditure, FDA approvals, and product launches
    in the hypertriglyceridemia therapeutics market.
    For instance, in July 2016, Mylan launched
    Rosuvastatin Calcium Tablets in the U.S., which
    are the generic version of Crestor (AstraZenecas
    tablet). The company received the U.S. Food and
    Drug Administration (FDA) approval for their ANDA
    (Abbreviated New Drug Application). Crestor
    tablets are used in combination with diet for
    treating hypertriglyceridemia in adults.

  • Moreover, the growing prevalence of obesity in
    the U.S. is projected to boost the growth of the
    regional market during the forecast period. For
    instance, according to the Centers for Disease
    Control and Prevention (CDC), the prevalence of
    obesity in the U.S. was 42.4 in 2017 and the
    rate is increasing at a rapid pace.
  • Furthermore, the market in Asia Pacific is
    expected to witness significant growth during the
    forecast period owing to drug approvals and surge
    in prevalence of cardiovascular diseases in the
    region. As per the Department of Nutrition and
    Health Sciences, cardiac problems account for
    seven out of every 10 deaths in Asian countries.

  • Figure 2. Global Hypertriglyceridemia
    Therapeutics Market Value (US Mn) Y-o-Y Growth
    (), 2017-2027

Global Hypertriglyceridemia Therapeutics Market -
Competitive Landscape
  • Key players operating in the global
    hypertriglyceridemia therapeutics market are
    Sanofi, GlaxoSmithKline Plc, Biocon, Novo Nordisk
    A/S, Tonghua Dongbao Pharmaceutical Co., Ltd.,
    Oramed Pharmaceuticals, Inc, Merck Co., Inc.,
    Julphar, Eli Lilly and Company, Bristol-Myers
    Squibb Company, Pfizer Inc., Adocia, Hikma
    Pharmaceutical plc, Lupin Ltd., AbbVie Inc.,
    Wockhardt Ltd., Zydus Pharmaceuticals, Glenmark
    Pharmaceuticals, Amneal pharmaceutical LLC,
    Aurobindo Pharma, and Accord Healthcare.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Reference https//www.coherentmarketinsights.com/

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com